Sun Pharmaceutical Industries Limited is an international speciality pharma company is s a Large Cap company with a market capital of Rs 100076.26Crore.

Sun Pharmaceuticals was established by Mr. Dilip Shanghvi in 1983 in Vapi, Gujarat.. It was reconstituted as a limited company in 1993.By the end of 2019, the company has a total of 2,399,334,970 shares outstanding.

Their products are prescribed in chronic therapy areas like cardiology, psychiatry, neurology, gastroenterology, diabetology and respiratory.The company also makes active pharmaceutical ingredients.

In 2014 Sun Pharmaacquired Ranbaxy, which makes the company the largest pharma company in India, the largest Indian pharma company in the US, and the 5th largest speciality generic company globally.

The United States is the single largest market of Sun Pharma with over 50% of their turnover is from USA.

With about 30% revenue from rest-of-the world (excluding India and US), Sun Pharma is amongst the largest Indian companies in the emerging markets. Europe, Canada, Japan, Australia contribute 11% and 19% is from emerging markets of Brazil, Russia, Romania, South Africa and others.

CRISIL Ltd. has assigned the highest credit rating of ‘CRISIL A1+ and CRISIL AAA/Stable’ for short term & long-term bank facilities and commercial paper programs of the Company.

On 10th of April, Sun Pharmaceuticals Industries regains Rs 1 trillion m-cap after surging 38% in four days, Sun Pharma’s shares were trading higher for the fourth straight day, up 8.5 per cent to Rs 474 on the BSE.

If you find any mistake please contact the support@largecapindia.com. This article is general in nature. It does not constitute a recommendation to buy and sell any stock, and does not take account of your objectives, or your financial situation. Largecapindia has no position in the stocks mentioned.

Largecapindia aim to bring you long term focused research analysis driven by fundamental thanks you.

For More Info : https://www.largecapindia.com